| Date | Title | Description | |
|---|---|---|---|
| 12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 30 Jun 2022 | Other relevant information | The Company informs about the dividends payment | Download |
| 16 Jun 2022 | Other relevant information | The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs | Download |
| 14 Jun 2022 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
| 11 May 2022 | On business and financial situation | The Company releases the first quarter 2022 financial results presentation | Download |
| 11 May 2022 | Announcement of general shareholders’ meeting | Rovi releases the information related to its 2022 General Shareholders Meeting | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 06 Nov 2018 | Información sobre resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2018 results. | Download |
| 06 Nov 2018 | Información sobre resultados | ROVI releases the press release related to the nine-month period ended 30 September 2018 results. | Download |
| 17 Oct 2018 | Buy-back programmes, stabilisation and treasury stock | ROVI informs of the resumption of operations with own shares under the liquidity contract | Download |
| 17 Oct 2018 | Buy-back programmes, stabilisation and treasury stock | ROVI informs that Jefferies International Limited has exercised, in full, the greenshoe subscription option | Download |
| 08 Oct 2018 | Share capital increases and reductions | Information on new shares admissions related to the capital increase of ROVI | Download |